Lv12
24 积分 2025-09-10 加入
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
11小时前
待确认
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
1天前
已完结
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
1天前
已完结
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
1天前
已完结
Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
16天前
已完结
Whole-genome landscapes of 1,364 breast cancers
24天前
已完结
A TNFR2–hnRNPK Axis Promotes Primary Liver Cancer Development via Activation of YAP Signaling in Hepatic Progenitor Cells
27天前
已完结
Liver cancer heterogeneity modeled by in situ genome editing of hepatocytes
29天前
已完结
Trastuzumab Deruxtecan and Sacituzumab Govitecan for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer: A Cost-Effectiveness Analysis
1个月前
已完结
ETS1 is a key transcription factor that drives RANKL-expressing, tissue-destructive fibroblasts
2个月前
已完结
皖公网安备34019202002308
